Table 3.
Multivariate analysis for main outcomes.
| HR | 95%CI per HR | p-value | ||
|---|---|---|---|---|
| Lower | Upper | |||
| OS | ||||
| Age ≥60 vs. <60 | 2.157 | 1.286 | 3.616 | 0.004 |
| HCT-CI ≥3 vs. <3 | 1.233 | 0.733 | 2.076 | 0.430 |
| DRI H/VH vs. L/I | 1.913 | 1.081 | 3.386 | 0.026 |
| MMUD vs. MRD | 1.253 | 0.636 | 2.470 | 0.515 |
| MUD vs. MRD | 1.543 | 0.875 | 2.722 | 0.134 |
| ATLG vs. no ATLG | 1.205 | 0.606 | 2.395 | 0.594 |
| PFS | ||||
| Age ≥60 vs. <60 | 1.588 | 0.972 | 2.596 | 0.065 |
| HCT-CI ≥3 vs. <3 | 1.242 | 0.764 | 2.019 | 0.383 |
| DRI H/VH vs. L/I | 2.304 | 1.351 | 3.930 | 0.002 |
| MMUD vs. MRD | 1.335 | 0.704 | 2.530 | 0.376 |
| MUD vs. MRD | 1.880 | 1.117 | 3.167 | 0.018 |
| ATLG vs. no ATLG | 1.281 | 0.671 | 2.447 | 0.453 |
| TRM | ||||
| Age ≥60 vs. <60 | 3.072 | 1.381 | 6.831 | 0.006 |
| HCT-CI ≥3 vs. <3 | 1.449 | 0.647 | 3.245 | 0.367 |
| DRI H/VH vs. L/I | 1.209 | 0.445 | 3.285 | 0.709 |
| MMUD vs. MRD | 1.398 | 0.528 | 3.700 | 0.500 |
| MUD vs. MRD | 1.734 | 0.585 | 5.142 | 0.321 |
| ATLG vs. no ATLG | 2.230 | 0.922 | 5.394 | 0.075 |
| RI | ||||
| Age ≥60 vs. <60 | 1.115 | 0.586 | 2.122 | 0.741 |
| HCT-CI ≥3 vs. <3 | 1.072 | 0.581 | 1.979 | 0.824 |
| DRI H/VH vs. L/I | 3.086 | 1.664 | 5.724 | <0.001 |
| MMUD vs. MRD | 1.061 | 0.466 | 2.415 | 0.889 |
| MUD vs. MRD | 1.607 | 0.865 | 2.984 | 0.133 |
| ATLG vs. no ATLG | 1.029 | 0.446 | 2.378 | 0.946 |
CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TRM, transplant-related mortality; RI, relapse incidence; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; DRI, disease risk index; H, high; VH, very high; L, low; I, intermediate; MMUD, 9/10-mismatched unrelated donor; MUD, 10/10-matched unrelated donor; ATLG, anti T-lymphocyte globulin.
Bold values were statistically significant.